Terrence L. Fisher
Research Subjects
Terrence L. Fisher has a total of 38 co-authors. Here are the top co-authors by number of shared publications:
Ernest Smith
Vaccinex, Inc., Rochester, New York
2 shared publicationsMaurice Zauderer
Vaccinex, Inc., Rochester, New York
2 shared publications- Aaron Scott Mansfield
Mayo Clinic
1 shared publication Alexander I. Spira
Virginia Cancer Specialists and US Oncology Research, The Woodlands, Texas
1 shared publication- Amita Patnaik
START, San Antonio, TX
1 shared publication Andreas Schröder
Merck KGaA, Darmstadt, Germany
1 shared publication
Latest Publications
- Open Access
- 5 April 2021
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 27 (13) , 3630-3640
A Phase Ib/II Study of Pepinemab in Combination with Avelumab in Advanced Non–Small Cell Lung Cancer
Purpose: The CLASSICAL-Lung clinical trial tested the combination of pepinemab, an IgG4 humanized mAb targeting semaphorin 4D, with the PD-L1 inhibitor avelumab to assess the effects of coupling increased T-cell infiltration and reversal of immune suppression via pepinemab with sustained T-cell activation via checkpoint inhibition. Patients and Methods: This phase Ib/II, single-arm study was designed to evaluate the safety, tolerability, and efficacy of pepinemab in combination with avelumab in 62 patients with advanced non–small cell lung cancer (NSCLC), including immunotherapy-naïve (ION) patients and patients whose tumors progressed following anti-PD-1/L1 monotherapy (IOF). The main objectives were to evaluate safety/tolerability, establish a recommended phase 2 dose (RP2D), obtain a preliminary evaluation of antitumor activity, and investigate candidate biomarker activity. Results: The combination was well tolerated with no major safety signals identified. Pepinemab, 10 mg/kg with avelumab, 10 mg/kg, every 2 weeks, was selected as the RP2D. Among 21 evaluable ION patients, 5 patients experienced partial responses (PR), 4 patients evidenced clinical benefit ≥1 year, and the disease control rate (DCR) was 81%. Notably, overall response rate with the combination therapy was higher than previously reported for single-agent avelumab in the PD-L1-negative/low population. Among 29 evaluable IOF patients, the combination resulted in a DCR of 59%, including 2 PR and 7 patients with durable clinical benefit of ≥23 weeks. Biomarker analysis of biopsies demonstrated increased CD8 T-cell density correlating with RECIST response criteria. Conclusions: The combination of pepinemab with avelumab was well tolerated in NSCLC and showed signs of antitumor activity in immunotherapy-resistant and PD-L1-negative/low tumors.
- 5 April 2021
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 27 (13) , 3630-3640
Open AccessA Phase Ib/II Study of Pepinemab in Combination with Avelumab in Advanced Non–Small Cell Lung Cancer
Purpose: The CLASSICAL-Lung clinical trial tested the combination of pepinemab, an IgG4 humanized mAb targeting semaphorin 4D, with the PD-L1 inhibitor avelumab to assess the effects of coupling increased T-cell infiltration and reversal of immune suppression via pepinemab with sustained T-cell activation via checkpoint inhibition. Patients and Methods: This phase Ib/II, single-arm study was designed to evaluate the safety, tolerability, and efficacy of pepinemab in combination with avelumab in 62 patients with advanced non–small cell lung cancer (NSCLC), including immunotherapy-naïve (ION) patients and patients whose tumors progressed following anti-PD-1/L1 monotherapy (IOF). The main objectives were to evaluate safety/tolerability, establish a recommended phase 2 dose (RP2D), obtain a preliminary evaluation of antitumor activity, and investigate candidate biomarker activity. Results: The combination was well tolerated with no major safety signals identified. Pepinemab, 10 mg/kg with avelumab, 10 mg/kg, every 2 weeks, was selected as the RP2D. Among 21 evaluable ION patients, 5 patients experienced partial responses (PR), 4 patients evidenced clinical benefit ≥1 year, and the disease control rate (DCR) was 81%. Notably, overall response rate with the combination therapy was higher than previously reported for single-agent avelumab in the PD-L1-negative/low population. Among 29 evaluable IOF patients, the combination resulted in a DCR of 59%, including 2 PR and 7 patients with durable clinical benefit of ≥23 weeks. Biomarker analysis of biopsies demonstrated increased CD8 T-cell density correlating with RECIST response criteria. Conclusions: The combination of pepinemab with avelumab was well tolerated in NSCLC and showed signs of antitumor activity in immunotherapy-resistant and PD-L1-negative/low tumors.
- Open Access
- 13 November 2015
- Published by Wiley in Cytometry Part B: Clinical Cytometry
- Vol. 90 (2) , 199-208
Saturation monitoring of VX15/2503, a novel semaphorin 4D‐specific antibody, in clinical trials
Background: Receptor occupancy, or saturation, assays are often utilized in preclinical and clinical development programs to evaluate the binding of a biologic to a cellular target. These assays provide critical information regarding the dose of drug required to “saturate” the target as well as important pharmacodymamic (PD) data. A flow cytometric method was developed to measure the degree of Semaphorin 4D (SEMA4D; CD100) saturation by VX15/2303, an investigational monoclonal antibody specific for SEMA4D.Methods: The assay detects VX15/2503, a human IgG4 specific for SEMA4D, with an IgG4‐specific monoclonal antibody.Results: Data generated allowed assessment of two related SEMA4D‐specific pharmacodynamic (PD) markers: (1) The measurement of cellular SEMA4D (cSEMA4D) saturation by VX15/2503, and (2) the cell membrane expression levels of cSEMA4D.Conclusions: This assay specifically and reproducibly measured cSEMA4D saturation and expression levels. Evaluation of the SEMA4D‐specific PD markers were critical in determining the clinical saturation threshold of cSEMA4D by VX15/2503. © 2015 he Authors Cytometry Part B: Clinical Cytometry Published by Wiley Periodicals, Inc.
- 13 November 2015
- Published by Wiley in Cytometry Part B: Clinical Cytometry
- Vol. 90 (2) , 199-208
Open AccessSaturation monitoring of VX15/2503, a novel semaphorin 4D‐specific antibody, in clinical trials
Background: Receptor occupancy, or saturation, assays are often utilized in preclinical and clinical development programs to evaluate the binding of a biologic to a cellular target. These assays provide critical information regarding the dose of drug required to “saturate” the target as well as important pharmacodymamic (PD) data. A flow cytometric method was developed to measure the degree of Semaphorin 4D (SEMA4D; CD100) saturation by VX15/2303, an investigational monoclonal antibody specific for SEMA4D.Methods: The assay detects VX15/2503, a human IgG4 specific for SEMA4D, with an IgG4‐specific monoclonal antibody.Results: Data generated allowed assessment of two related SEMA4D‐specific pharmacodynamic (PD) markers: (1) The measurement of cellular SEMA4D (cSEMA4D) saturation by VX15/2503, and (2) the cell membrane expression levels of cSEMA4D.Conclusions: This assay specifically and reproducibly measured cSEMA4D saturation and expression levels. Evaluation of the SEMA4D‐specific PD markers were critical in determining the clinical saturation threshold of cSEMA4D by VX15/2503. © 2015 he Authors Cytometry Part B: Clinical Cytometry Published by Wiley Periodicals, Inc.
- 20 May 2014
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 32 (15_suppl) , 3052
Phase 1 study of VX15/2503, a humanized IgG4 anti-SEMA4D antibody, in advanced cancer patients (pts).
3052^ Background: Semaphorin 4D (SEMA4D) regulates cellular adhesion, motility and activation of cells of the nervous, vascular and immune systems; it also promotes tumor progression and metastasis. SEMA4D and its receptor plexin B1 are widely expressed in human tumors; the interaction of plexin B1 with MET and ERBB2 leads to SEMA4D-mediated transactivation of these membrane receptor kinases promoting tumor cell migration and invasive growth. The murine progenitor of VX15/2503 suppressed tumor growth in syngeneic and transgenic tumors. No toxicologic effects were noted in studies of VX15/2503 using rats and primates and PK/PD profiles were generally predictive of data from clinical trial subjects. Methods: A multiple ascending dose trial was initiated in adult pts with advanced refractory solid tumors; pts were administered weekly IV doses of VX15/2503 until progression. Dose levels were 0.3 to 20 mg/kg. Tumors were assessed by RECIST 1.1 after each 8 dose cycle. Biomarkers assessed were SEMA4D, VEGF, HGF, PLGF, and MET. Results: Enrollment has been concluded (n=42 Pts); sex 40.5%M/59.5%F. Mean age (yrs) 64.8; ECOG 0/1/2 are 28.6% /69%/4%. No MTD was found. One DLT (grade 3 GGT elevation; 15 mg/kg) was reported in a pancreatic cancer pt with disease progression. As of 12/16/2013 the most frequent treatment-related AE’s (n=42 pts) included grade 1/2 nausea (11.7%), arthralgia (7.3%), decreased appetite (7.3%), and fatigue (7.3%); 15 drug unrelated SAE’s were reported in 11 pts. No CR/PR were observed. Thirteen of 42 pts at all dose levels exhibited stable disease for at least 8 weeks. Pts with the longest duration of treatment included: 48-55 weeks (colorectal; 9 mg/kg) (breast; 15 mg/kg) (papillary thyroid; 20 mg/kg); these pts had relatively high T or B cell levels. VX15/2503 serum concentrations of ≥ 0.3 µg/mL produced complete T cell SEMA4D saturation. HAHA responses (titer > 100) with possible effects on PK were observed in 4 of 41 pts (10%); in only 1 pt (2%) was an effect of HAHA on PD observed. VX15/2503 half-life was roughly 4-5 days at doses ≥1.0 mg/kg. Conclusions: VX15/2503 was well tolerated at dose levels up to 20 mg/kg, with 450 doses administered to 42 pts. Future studies will be combination trials in selected tumor types. Clinical trial information: NCT01313065.
- 20 May 2014
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 32 (15_suppl) , 3052
Phase 1 study of VX15/2503, a humanized IgG4 anti-SEMA4D antibody, in advanced cancer patients (pts).
3052^ Background: Semaphorin 4D (SEMA4D) regulates cellular adhesion, motility and activation of cells of the nervous, vascular and immune systems; it also promotes tumor progression and metastasis. SEMA4D and its receptor plexin B1 are widely expressed in human tumors; the interaction of plexin B1 with MET and ERBB2 leads to SEMA4D-mediated transactivation of these membrane receptor kinases promoting tumor cell migration and invasive growth. The murine progenitor of VX15/2503 suppressed tumor growth in syngeneic and transgenic tumors. No toxicologic effects were noted in studies of VX15/2503 using rats and primates and PK/PD profiles were generally predictive of data from clinical trial subjects. Methods: A multiple ascending dose trial was initiated in adult pts with advanced refractory solid tumors; pts were administered weekly IV doses of VX15/2503 until progression. Dose levels were 0.3 to 20 mg/kg. Tumors were assessed by RECIST 1.1 after each 8 dose cycle. Biomarkers assessed were SEMA4D, VEGF, HGF, PLGF, and MET. Results: Enrollment has been concluded (n=42 Pts); sex 40.5%M/59.5%F. Mean age (yrs) 64.8; ECOG 0/1/2 are 28.6% /69%/4%. No MTD was found. One DLT (grade 3 GGT elevation; 15 mg/kg) was reported in a pancreatic cancer pt with disease progression. As of 12/16/2013 the most frequent treatment-related AE’s (n=42 pts) included grade 1/2 nausea (11.7%), arthralgia (7.3%), decreased appetite (7.3%), and fatigue (7.3%); 15 drug unrelated SAE’s were reported in 11 pts. No CR/PR were observed. Thirteen of 42 pts at all dose levels exhibited stable disease for at least 8 weeks. Pts with the longest duration of treatment included: 48-55 weeks (colorectal; 9 mg/kg) (breast; 15 mg/kg) (papillary thyroid; 20 mg/kg); these pts had relatively high T or B cell levels. VX15/2503 serum concentrations of ≥ 0.3 µg/mL produced complete T cell SEMA4D saturation. HAHA responses (titer > 100) with possible effects on PK were observed in 4 of 41 pts (10%); in only 1 pt (2%) was an effect of HAHA on PD observed. VX15/2503 half-life was roughly 4-5 days at doses ≥1.0 mg/kg. Conclusions: VX15/2503 was well tolerated at dose levels up to 20 mg/kg, with 450 doses administered to 42 pts. Future studies will be combination trials in selected tumor types. Clinical trial information: NCT01313065.